Description: This session will uncover the mystical findings that can be uncovered when leveraging a reinsurer. Insights discussed during this session include mortality at high face amounts, interactions between lapses and mortality, mortality improvement on low face amounts, fully underwritten mortality by Resident State and more. At the conclusion of this session, attendees will be able to identify where reinsurer data can help uncover insights, how mortality and lapse knowledge can improve product performance and what some mortality results can come from reinsurance research.

Description: Given the rise in interest rates during 2023, the session will discuss the implication of increasing rates on FA and FIA business by looking at industry experience for FA and FIA products for 2023 and earlier years. Additionally, the session will walk through partial withdrawals, GLWB utilization, mortality and what to expect as interest rates volatile continues. The session will also discuss how direct writers and reinsurers are handing the inforce management aspects of these products in the uncertain and volatile economic periods.

Description: By attending the session, you will learn: - Different perspectives around what FP&A is used for (e.g., strategic planning, performance measurement, management compensation, liquidity management, etc.) and why - Challenges leaders have faced and how they are being addressing - How recent regulatory, accounting, and technological change has impacted the FP&A function - Objectives for various organizations around both new analytics for business management, efficient production of forecast results, and potential for faster 'top down' forecasting

Description: Over the last few years, a significant amount of US annuity and pension business has been reinsured with offshore companies, both affiliated and non-affiliated. Hear experts discuss different reserve and capital regimes between the US and offshore jurisdictions, as well as US regulator concerns and responses. The attendees will learn the reasons companies use offshore reinsurance, and improve their understanding of the discussion of proposals to increase US regulator and consumer comfort with companies outside of US jurisdiction.

Description: Value of new business (VNB) is being used by many companies for various purposes including: internal and external financial reporting, incentive compensation, pricing, capital management, and comparing products, distribution channels or regions on a consistent basis. Presenters will discuss how and why value of new business is used within their companies including: the various methodologies considered, some of the benefits and challenges related to implementing VNB, integrating VNB within their business as usual processes, and managing to VNB.

Description: El webcast presentará una comparación de alto nivel de los acuerdos internacionales de financiamiento de la atención de la salud y proporcionará una comparación y contrato con los modelos de Colombia y otros modelos latinoamericanos.

Description: Generally accepted accounting practices (GAAP) reporting frameworks are more involved than ever before. From disclosures, to assumption changes, to interest rate movements, uncovering the drivers of income emergence can prove hard to do, and even trickier to communicate. This session will revisit how the updated standards create layers of complexity and offer ways to side step these obstacles to generate useful earnings analysis by various drivers.

Description: In this webinar, the presenters will give a behind the scenes look at how the NAIC ESG was parameterized. They will also share the results of its most recent calibration.

Description: Medicare Advantage plans have been in the market for two decades. In this session, we survey the landscape changes from 2006 up to now, which include but not limited to the changes of enrollment, plan types, big players' market share, policies, and how players as well as beneficiaries react to the changes. This session intends to provide general MA knowledge and history to the audience with or without Medicare Advantage background.

Description: A new wave of biosimilar launches is creating downward pressure on average sales prices (ASPs), disrupting reimbursement to providers, providing opportunities and challenges to payers and GPOs, and upending the gross-to-net math for manufacturers. In this session, we will explore the implications of the ASP death spiral on the drug supply chain and its interplay with price transparency efforts.